Market Place
Sourcing Support
Can-Fite Doses First Patient in Pancreatic Cancer Phase IIa Trial
11 Nov 2024 //
GLOBENEWSWIRE
Can-Fite’s Namodenoson Receives Patent Allowance in Australia
04 Nov 2024 //
GLOBENEWSWIRE
Positive Osteoarthritis Results In Dogs Treated With Piclidenoson
18 Oct 2024 //
GLOBENEWSWIRE
FDA Grants Orphan Drug To Can-Fite`s Namodenoson
09 Oct 2024 //
GLOBENEWSWIRE
Can-Fite Announces Live Investor Webinar On October 29
07 Oct 2024 //
GLOBENEWSWIRE
Can-Fite Projects $325M Over 10 Years from Piclidenoson License
24 Sep 2024 //
GLOBENEWSWIRE
Can-Fite: Namodenoson Study Approved By Israeli Ministry
16 Sep 2024 //
GLOBENEWSWIRE
Can-Fite Reports H1 2024 Financial Results and Phase III Clinical Progress
29 Aug 2024 //
GLOBENEWSWIRE
Can-Fite Announces Warrant Exercise For $5M Gross Proceeds
08 Aug 2024 //
GLOBENEWSWIRE
Can-Fite Provides Namodenoson Patent Update
29 Jul 2024 //
GLOBENEWSWIRE
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
17 Jul 2024 //
GLOBENEWSWIRE
Can-Fite Seeks FDA Orphan Drug Status For Namodenoson In Pancreatic Cancer
11 Jul 2024 //
GLOBENEWSWIRE
Patient Improvement Reported With Namodenoson In Liver Cirrhosis
01 Jul 2024 //
GLOBENEWSWIRE
Can-Fite`s Partner Vetbiolix Reports Results in Osteoarthritis Study in Dogs
28 Jun 2024 //
BUSINESSWIRE
Can-Fite demonstrates Namodenoson`s anticancer and liver protective effects.
24 Jun 2024 //
BUSINESSWIRE
Can-Fite Gets IRB Approval For Pancreatic Cancer Study With Namodenoson
10 Jun 2024 //
BUSINESSWIRE
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
05 Jun 2024 //
BUSINESSWIRE
Can-Fite Bio 2024 Partnering: International Convention Meeting Participation
27 May 2024 //
BUSINESSWIRE
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
23 May 2024 //
BUSINESSWIRE
Can-Fite Hosts Conference To Accelerate Liver Cancer Study Enrollment
13 May 2024 //
BUSINESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson
09 May 2024 //
BUSINESSWIRE
Can-Fite receives European Patent for CF602`s erectile dysfunction treatment.
06 May 2024 //
BUSINESSWIRE
Can-Fite: Namodenoson Long-Term CR in Advanced Liver Cancer Patient
25 Apr 2024 //
BUSINESSWIRE
Can-Fite: Namodenoson Promising For Liver Cancer, MASH
15 Apr 2024 //
BUSINESSWIRE
Can-Fite: Submits an IND Application to Conduct Ph IIb Trial of Namodenoson
03 Apr 2024 //
BUSINESSWIRE
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 2024 //
BUSINESSWIRE
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH
28 Feb 2024 //
BUSINESSWIRE
Can-Fite Expands the Out-Licensing Deal with Ewopharma
30 Jan 2024 //
BUSINESSWIRE
Can-Fite:Journal Published Positive Data from the COMFORT-1 PIII Psoriasis Study
29 Jan 2024 //
BUSINESSWIRE
The Anti-Obesity Effect of Can-Fite’s Namodenoson
20 Dec 2023 //
BUSINESSWIRE
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
18 Dec 2023 //
BUSINESSWIRE
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients
04 Dec 2023 //
BUSINESSWIRE
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
30 Nov 2023 //
PRESS RELEASE
Can-Fite:Complete Response in Patient with Liver Cancer Treated with Namodenoson
21 Nov 2023 //
BUSINESSWIRE
Can-Fite Announces Exercise of Warrants for $3.0M in Gross Proceeds
21 Nov 2023 //
GLOBENEWSWIRE
Can-Fite Issues Business Update
01 Nov 2023 //
BUSINESSWIRE
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
26 Oct 2023 //
BUSINESSWIRE
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment
09 Oct 2023 //
BUSINESSWIRE
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma
27 Sep 2023 //
BUSINESSWIRE
Can-Fite to Share with Investors Oncology and Rare Genetic Disease Developments
07 Sep 2023 //
BUSINESSWIRE
Can-Fite Reports 2Q 2023 FYR & Progress in Two Pivotal PhIII Clinical Studies
31 Aug 2023 //
BUSINESSWIRE
Can-Fite Enters Rare Disease Field Based on findings of a Fondazione Telethon
24 Aug 2023 //
BUSINESSWIRE
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson
18 Aug 2023 //
BUSINESSWIRE
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson
17 Jul 2023 //
BUSINESSWIRE
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
07 Jul 2023 //
BUSINESSWIRE
Can-Fite Receives USFDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
29 Jun 2023 //
BUSINESSWIRE
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients
13 Jun 2023 //
BUSINESSWIRE
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings
02 Jun 2023 //
BUSINESSWIRE
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
01 Jun 2023 //
BUSINESSWIRE
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives from (ASCO)
30 May 2023 //
BUSINESSWIRE
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication
15 May 2023 //
BUSINESSWIRE
Can-Fite to Exploratory Ph2 Trial Namodenoson in Pancreatic Cancer Patients
09 May 2023 //
BUSINESSWIRE
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves
24 Apr 2023 //
BUSINESSWIRE
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
30 Mar 2023 //
BUSINESSWIRE
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Companies
16 Mar 2023 //
BUSINESSWIRE
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson
13 Mar 2023 //
BUSINESSWIRE
Novel Approach to Treating Liver Cancer with Namodenoson Published in Journal
14 Feb 2023 //
BUSINESSWIRE
Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies
24 Jan 2023 //
BUSINESSWIRE
Can-Fite Announces $7.5M Registered Direct Offering and Private Placement
11 Jan 2023 //
BUSINESSWIRE
Can-Fite Submits Market Registration Plan to EMA for Piclidenoson
10 Jan 2023 //
BUSINESSWIRE
